Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Acurx Pharmaceuticals LLC (ACXP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: ACXP (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -45.3% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 8.75M USD | Price to earnings Ratio - | 1Y Target Price 6.7 |
Price to earnings Ratio - | 1Y Target Price 6.7 | ||
Volume (30-day avg) 388715 | Beta -1.71 | 52 Weeks Range 0.38 - 3.33 | Updated Date 04/1/2025 |
52 Weeks Range 0.38 - 3.33 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.87 |
Earnings Date
Report Date 2025-03-17 | When Before Market | Estimate -0.18 | Actual -0.16 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -152.41% | Return on Equity (TTM) -534.03% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 5134538 | Price to Sales(TTM) - |
Enterprise Value 5134538 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -3.54 | Shares Outstanding 22042500 | Shares Floating 19357072 |
Shares Outstanding 22042500 | Shares Floating 19357072 | ||
Percent Insiders 11.67 | Percent Institutions 9.8 |
Analyst Ratings
Rating 4 | Target Price 11.19 | Buy 2 | Strong Buy - |
Buy 2 | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Acurx Pharmaceuticals LLC
Company Overview
History and Background
Acurx Pharmaceuticals LLC is a biopharmaceutical company focused on developing new antibiotics for difficult-to-treat infections. It was founded to address the growing threat of antibiotic resistance.
Core Business Areas
- Antibiotic Development: Focuses on developing and commercializing innovative antibiotics to combat antibiotic-resistant bacteria.
Leadership and Structure
The leadership team consists of experienced professionals in the pharmaceutical industry, including clinical development, regulatory affairs, and commercialization. The company structure is typical of a small, research-driven biopharmaceutical firm.
Top Products and Market Share
Key Offerings
- Ibezapolstat: Ibezapolstat is a Phase 3 drug candidate for the treatment of Clostridioides difficile infection (CDI). Market share information is not readily available as it is not yet approved. Competitors include Merck's Dificid (fidaxomicin) and Vabomere.
Market Dynamics
Industry Overview
The antibiotics market faces increasing challenges due to antibiotic resistance and regulatory hurdles, but there is a continued need for new therapies, especially for difficult-to-treat infections.
Positioning
Acurx is positioned as a company focused on developing novel antibiotics, specifically targeting unmet needs in the treatment of CDI.
Total Addressable Market (TAM)
The global CDI market is estimated to be worth billions of dollars annually. Acurx is positioned to capture a portion of this TAM with its novel antibiotic candidate.
Upturn SWOT Analysis
Strengths
- Novel antibiotic candidate (Ibezapolstat)
- Focus on unmet medical needs
- Experienced management team
Weaknesses
- Limited financial resources
- Dependence on a single drug candidate
- Lack of commercial infrastructure
Opportunities
- Potential for FDA approval and commercialization of Ibezapolstat
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline with new antibiotic candidates
Threats
- Regulatory hurdles
- Competition from established antibiotics
- Failure of clinical trials
- Difficulty in securing funding
Competitors and Market Share
Key Competitors
- MRK
- MTNB
Competitive Landscape
Acurx's advantage lies in its novel mechanism of action, if proven to be superior or have some advantage over the current competition. Its disadvantage is that it is a smaller company competing against larger, established pharmaceutical companies.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historically, Acurx's growth has been characterized by the progression of Ibezapolstat through clinical trials.
Future Projections: Future growth depends heavily on the successful completion of Phase 3 trials and potential FDA approval. Analyst projections would factor in potential market share and pricing.
Recent Initiatives: Recent initiatives include ongoing Phase 3 clinical trials for Ibezapolstat and efforts to secure funding for future development.
Summary
Acurx Pharmaceuticals is a high-risk, high-reward biopharmaceutical company. Its success hinges on the clinical and regulatory success of Ibezapolstat. Securing additional funding and navigating the competitive landscape of established antibiotics are key challenges. If successful, Acurx could fill a significant need in the treatment of CDI.
Similar Companies
- MRK
- MTNB
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Industry reports
- Analyst reports
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It is not investment advice. Please consult with a financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Acurx Pharmaceuticals LLC
Exchange NASDAQ | Headquaters Staten Island, NY, United States | ||
IPO Launch date 2021-06-25 | Co-Founder, President, CEO, Corporate Secretary & Director Mr. David P. Luci CPA, Esq., J.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 4 | Website https://www.acurxpharma.com |
Full time employees 4 | Website https://www.acurxpharma.com | ||
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.